

# Chronic Obstructive Pulmonary Disease: Market Research Report

<https://marketpublishers.com/r/CA3C30DE511EN.html>

Date: February 2010

Pages: 432

Price: US\$ 3,450.00 (Single User License)

ID: CA3C30DE511EN

## Abstracts

This report analyzes the worldwide markets for Chronic Obstructive Pulmonary Disease in US\$ Million.

The report provides separate comprehensive analytics for US and Rest of World.

Annual forecasts are provided for each region for the period 2006 through 2015.

The report profiles 53 companies including many key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A.

SICAR, Schering-Plough Corporation, Sepracor, Inc., and Vectura Group plc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1.INDUSTRY OVERVIEW

Respiratory Diseases – Common and Serious  
COPD – A Debilitating Disease  
COPD Fact File: Prevalence  
COPD Fact File: Mortality  
COPD Fact File: Smoking as the Leading Cause  
COPD - Economic Burden

**Table 1.** COPD Related Costs (Including Direct and Indirect Costs) Per Patient Aged Over 40 Years (includes corresponding Graph/Chart)

#### 2.MARKET DYNAMICS

Current & Future Analysis  
Market Overview  
Market Outlook  
Maintenance Therapies to Continue Lead  
Treatment of Inflammation – An Unmet Need  
Competitive Landscape

**Table 2.** World COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Symbicort, and Atrovent (includes corresponding Graph/Chart)

**Table 3.** World Leading Inhaled COPD/Asthma Drugs (2007): Value Sales for Advair,

Symbicort, Pulmicort, Flovent, Asmanex, Serevent, Foradil, Spiriva, Atrovent, Combivent (includes corresponding Graph/Chart)

### **3.COPD PIPELINE**

The COPD Drug Discovery

Bronchodilators Pipeline

List of Potential Bronchodilator (LABA Inhaled) Candidates in Drug Development Pipeline

List of Potential Bronchodilator (LAMA Inhaled) Candidates in Drug Development Pipeline

Anti-inflammatories Pipeline

List of Potential Anti-inflammatory (Inhaled Corticosteroid) Candidates in Drug Development Pipeline

List of Potential Anti-inflammation Agents (Anti- Leukotriene-oral) Candidates in Drug Development Pipeline

List of Potential Anti-inflammation Agents (Phosphodiesterase-4 Inhibitors-oral) Candidates in Drug Development Pipeline

Combination Products Pipeline

List of Potential Combination Products (LABA/ICS Combination-inhaled) in Drug Development Pipeline

List of Potential Combination Products (LABA/LAMA) in Drug Development Pipeline Pipeline Drugs with Novel Mode of Action

List of Novel Approaches to COPD Treatment in Drug Development Pipeline

### **4.CHRONIC OBSTRUCTIVE PULMONARY DISEASE – THE CONDITION AND TREATMENT**

Chronic Obstructive Pulmonary Disease – Synopsis

The Normal Lung Functioning

The Lung Functioning in COPD

Risk Factors

Signs and Symptoms

Diagnosis

The Misconception

Management Guidelines

GOLD Recommended Management of COPD: Stage 0

GOLD Recommended Management of COPD: Stage II

GOLD Recommended Management of COPD: Stage III

GOLD Recommended Management of COPD: Stage IV

Treatment Options

Therapeutic Options

Bronchodilators

Beta2-agonists

Short-acting Beta2-agonists

List of Prescription Short-acting Beta2-agonists

Long-acting Beta2-agonists

A Comparison of Leading Two LABAs : Salmeterol and Formoterol

List of Prescription Long-acting Beta2-agonists

Anticholinergics

Short-acting Anticholinergics

List of Short-acting Prescription Anticholinergics

Long-acting Anticholinergics

Methylxanthines

List of Methylxanthines and Their Route of Administration

Anti-inflammatories

Inhaled Steroids

List of Inhaled Steroids and their Route of Administration

Oral Steroids

List of Tablet Steroids and their Route of Administration

Combination Therapies

List of Prescription Combination Products

## **5.RECENT INDUSTRY ACTIVITY**

AEterna Zentaris Signs Agreement to Acquire All AEZS-130 Assets from Ardana

Nycomed and Forest Sign Exclusive US Accord for Daxas

Schering-Plough Revises Collaboration with Novartis

AstraZeneca Extends Research Collaboration with Dynavax

GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal for Adoair

SeQual Technologies and AOTI Form Partnership

Revotar Biopharma Secures Research Grant

Argenta Discovery Announces Milestone Achievement

Vectura Receives Milestone Payment

Vectura Inaugurates New Laboratory Facility

MicroDose Technologies Announces Name Change to MicroDose Therapeutx

Boehringer Ingelheim to Take Over Actimis Pharmaceuticals

Novartis to Acquire Pulmonary Unit of Nektar

Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition  
Sepracor, Arrow Announce Global Agreement for Combination Inhalation Solution  
Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement  
Sepracor, Arrow Sign Technology License and Development Agreement  
Teva Specialty Pharmaceuticals Announces Respiratory Deal with UCB

### **3M DRUG DELIVERY AND CAMBRIDGE CONSULTANTS SIGN EXCLUSIVE AGREEMENT**

Sanofi-aventis Announces Collaboration with Johns Hopkins University  
Lupin Enters Long-Term Accord with Forest Laboratories  
Ingen Signs Agreements with Batterjee Medical and Progressive International  
AstraZeneca, Silence Therapeutics Enter into Collaboration  
Vectura Announces Sandoz as Partner for VR315 and VR632  
Air Products Divests A&J Care and COPD Services  
Parion Sciences Receives Milestone Payment for Pulmonary Disease Drug  
Almirall Receives Payment from Forest Laboratories for Acridinium Bromide  
AstraZeneca Announces EPO Ruling for Symbicort Patent  
Inverness Medical Announces Alere Medical Acquisition  
Respironics Takes Over J.H. Emerson  
Alkermes Enters into Joint Collaboration with Indevus Pharmaceuticals  
Aradigm Enters into Collaboration Agreement with CyDex  
Critical Therapeutics and Dey Sign Co-Promotion Agreement

### **6.PRODUCT APPROVALS / INTRODUCTIONS**

AstraZeneca Wins US Approval for Symbicort  
Novartis Secures EC Approval for New Oral COPD Drug, Onbrez Breezhaler  
Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA  
Nycomed Files for Daxas® Approval with the FDA  
Novartis Receives FDA's CRL for Investigational COPD Bronchodilator, QAB149  
**3M DRUG DELIVERY LAUNCHES TWO NEW DRY POWDER INHALERS**  
GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50  
Dey's Perforomist Inhalation Solution Wins FDA Approval for COPD  
Boehringer, Pfizer Win EU Approval for Spiriva Respimat

### **7.FOCUS ON SELECT PLAYERS**

AstraZeneca Plc (UK)

Boehringer Ingelheim GmbH (Germany)  
GlaxoSmithKline PLC (UK)  
Novartis AG (Switzerland)  
Nycomed S.C.A. SICAR (Switzerland)  
Schering-Plough Corporation (US)  
Sepracor, Inc. (US)  
Vectura Group plc (UK)

## **8.GLOBAL MARKET PERSPECTIVE**

**Table 4.** World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 5.** World 10-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

## **III. MARKET**

### **1.THE UNITED STATES**

#### **A. MARKET ANALYSIS**

Current & Future Analysis  
COPD – Prevalence

**Table 6.** COPD Prevalence Data in American Adults Aged 18 Years and Over in the US (includes corresponding Graph/Chart)

Chronic Bronchitis Data

**Table 7.** Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Gender: 2007

**Table 8.** Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart)

**Table 9.** Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart)

Emphysema Data

**Table 10.** Emphysema - Breakdown of Chronic Bronchitis Patients by Gender: 2007

**Table 11.** Emphysema - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart)

**Table 12.** Emphysema - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart)

Market Overview

**Table 13.** US COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart)

**Table 14.** US COPD Market by Major Drugs (2006): Total Prescriptions for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart)

**Table 15.** US COPD/Asthma Market by Drug Class (2007 and 2008): Value Sales for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrienes, and Inhaled Anticholinergics/NSAIDs (includes corresponding Graph/Chart)

**Table 16.** US COPD/Asthma Market by Drug Class (2007 and 2008): Total Prescriptions for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrienes, and Inhaled Anticholinergics/NSAIDs (includes corresponding Graph/Chart)

**Table 17.** US COPD/Asthma Market by Leading Drugs (2007 and 2008): Value Sales for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart)

**Table 18.** US COPD/Asthma Market by Leading Drugs (2007 and 2008): Total Number of Prescriptions for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart)

Patient Non-compliance Hinders Market Growth  
Lack of Awareness – A Major Bottleneck for Market Growth  
HFA-propelled Inhalers End the CFC-propelled Inhalers Era  
Strategic Corporate Developments  
Product Approvals / Launches  
Select Players

## **B. MARKET ANALYTICS**

**Table 19.** US Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease – Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2.REST OF WORLD**

### **A. MARKET ANALYSIS**

Current & Future Analysis  
China  
Market Overview  
Strategic Corporate Developments  
Product Approvals  
Select Players

### **B. MARKET ANALYTICS**

**Table 20.** Rest of World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease – Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 56)



Region/CountryPlayers  
The United States  
Canada  
Japan  
Europe  
France  
Germany  
The United Kingdom  
Italy  
Rest of Europe  
Asia-Pacific (Excluding Japan)

## I would like to order

Product name: Chronic Obstructive Pulmonary Disease: Market Research Report

Product link: <https://marketpublishers.com/r/CA3C30DE511EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA3C30DE511EN.html>